Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 7, 2005

View Archived Issues

Millennium updates pipeline progress

Locteron begins phase I study for chronic hepatitis C

Satraplatin begins phase II study in metastatic breast cancer

Tm Bioscience develops upper respiratory viral panel

GTC Biotherapeutics and LEO Pharma enter agreement for ATryn

Positive outcome for BEMA-fentanyl in comparative pharmacokinetics study

Alnylam seeks clearance for phase I study of ALN-RSV01 for RSV

Antiviral FluCide-I begins preclinical studies

DOR BioPharma to acquire Gastrotech Pharma

NF-676: novel and potent use-dependent blocker of RyR1

SL-650155 reveals effects of serotonin in models of amnesia

ACTOplus met available in U.S. for type 2 diabetes

Novel agents for the treatment of neurological disorders disclosed in recent patents

Recent patents report compounds with potential use in the treatment of respiratory disorders

New treatments for cancer covered in recent patents

In vitro effects of anti-TNF-alpha agents on apoptosis and cytotoxicity

AT-001 reported effective in the treatment of rheumatoid arthritis

AmPrbetaCD: a novel anthrax lethal toxin inhibitor

Update on the therapeutic benefits of quetiapine in psychological disorders

Acadia presents a new potent, orally available, isoform-selective RARbeta2 agonist

Phase I data on tgAAC94 in inflammatory arthritis

Clinical evidence confirms transdermal selegiline is safe in patients with major depression

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 13, 2026.
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...
Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent
BioWorld Science
Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...